Arden Trust’s NovoCure NVCR Stock Holding History

Arden Trust’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,524	Closed	-$103K	–	619
2020 Q1	$103K	Buy	+1,524	New	+$120K	0.02%	379

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCP

Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return

Arden Trust's NVCR Position: Q2 2020 in Review

Arden Trust sold out of NovoCure (NVCR) in Q2 2020, closing a stake of 1,524 shares — an estimated $103K sold.

Arden Trust first reported a position in NVCR in Q1 2020 and held it in 1 quarter. The position peaked at $103K in Q1 2020. 264 funds tracked by Wall St. Rank hold NVCR as of Q2 2020.

Arden Trust reported no remaining NovoCure position as of Q2 2020 after selling out during the quarter.
Arden Trust sold 1,524 NovoCure shares in Q2 2020, an estimated $103K.
Arden Trust first reported a position in NovoCure in Q1 2020 and held it in 1 quarter.
Arden Trust's NovoCure position peaked at $103K in Q1 2020.
264 funds tracked by Wall St. Rank held NovoCure as of Q2 2020.

Based on Arden Trust's 13F filing for Q2 2020, filed 9 Jul 2020.